Sandip Patel, MD

Articles

Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study

June 29th 2023

David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC

Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

June 29th 2023

Overview and clinical implications of the CheckMate-816 study of neoadjuvant nivolumab plus platinum chemotherapy versus chemotherapy alone in early-stage NSCLC.

Selecting Optimal Treatment in Early-Stage NSCLC

June 23rd 2023

Ben Levy, MD offers insight into how he approaches the selection of the optimal treatment strategy in early-stage non-small cell lung cancer.

Overview of Early-Stage NSCLC and Molecular Testing

June 23rd 2023

A panel of experts who treat patients with non-small cell lung cancer provides an overview of staging, molecular testing and treatment options in stage I-IIIB non-small cell lung cancer.

Dr. Patel on Optimizing Molecular Testing for EGFR Mutations in Lung Cancer

January 26th 2022

Sandip P. Patel, MD, discusses optimizing molecular testing for EGFR mutations in lung cancer.

Dr. Patel Discusses Novel Targets in NSCLC

November 15th 2021

Sandip P. Patel, MD, discusses novel targets in non–small cell lung cancer.

Dr. Patel on the Utility of Consolidative Durvalumab in Stage III NSCLC

October 20th 2021

Sandip P. Patel, MD, discusses the utility of consolidative durvalumab in stage III non–small cell lung cancer.

Dr. Patel on the Potential With PARP/Immunotherapy Combos in NSCLC

July 30th 2021

Sandip P. Patel, MD, discusses the potential of combining PARP inhibitors with immunotherapy for patients with non–small cell lung cancer.

Dr. Patel on Benefit of Ipilimumab/Nivolumab Combo in High-Grade Neuroendocrine Carcinoma

April 3rd 2019

Sandip Patel, MD, associate professor of medicine at the University of California San Diego School of Medicine, discusses the benefit of the immune checkpoint inhibitor combination of ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with rare, high-grade neuroendocrine tumors.